Publisher's studies focus on China’s Healthcare Industry. In the two past decades, the industry has been growing at a fast pace. It is a tremendous challenge to provide healthcare for 1.3 billion people. The dramatic expansions of the healthcare system, drug manufacturing, and health insurance have transformed China’s society and economy. Life expectancy reached 76.8 for women and 72.5 for men now comparing to 69.9 for women and 66.9 for men in 1990. Demographic transition from high mortality to low mortality has helped increase life expectancy. Primary diseases have also shifted from infectious to chronic. Cancer, heart diseases and cerebrovascular diseases are now top killers. Spending on healthcare counts for over 5% of GDP now and continue to increase in the next decade.    

Healthcare reform has been one of the key topics on the government agenda in China. Due to the rise in the cost of healthcare, more than 10% of the income is spent on healthcare, which is greater than that spent on education and transportation. The rise in the cost in healthcare would definitely have an outcome of the high cost of the drugs. There are approximately 4,500 pharmaceutical companies in China, the majority of which are small players with limited local market reach. Rapid consolidation between medium and large players in the sector is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to better control the pricing of drugs.  

China is one of the world’s major producers of pharmaceuticals. Far outpacing other economies in the world, China is the world’s fastest growing pharmaceutical market. Although China has enjoyed the benefits of an expanding market for pharmaceutical production and distribution, the industry is suffering from minimal innovation and investment in R&D and new product development. The sector’s economies of scale have yet to be achieved. Most domestic manufacturers in the pharmaceutical industry lack the autonomic intellectual property and financial resources to develop their own brand name products. Most manufacturers rely on the repetitive production of Chinese medicine, low value-added bulk pharmaceuticals or generic drugs. 

Biotechnology is a rapidly growing sector in China. Both production and demand have witnessed significant surges in recent years. China will continue to remain a large importer for biotechnology pharmaceuticals to meet the growing domestic demand. Major imports include biotechnology vaccines, CSF, r-EPO, recombinant human insulin, recombinant human growth hormones, recombinant interferon, and other biotechnology pharmaceuticals.

The health care insurance industry of China includes two main parts such as the social healthcare insurance controlled by the government and commercial healthcare insurance provided by private companies. At present, the social healthcare insurance is under reforms to control the increasing healthcare costs. The development of commercial healthcare insurance in China is not inadequate. But the commercial healthcare insurance market has a great growth potential. Today, China has the largest healthcare market in the world. The Chinese healthcare industry is one of the fastest-growing sectors in China, growing at double digit rate each year. Tremendous fast-growing markets for imports and business opportunities for companies around the world.